This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Down -12.39% in 4 Weeks, Here's Why Neogen (NEOG) Looks Ripe for a Turnaround
by Zacks Equity Research
Neogen (NEOG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool
by Zacks Equity Research
Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on recent product launches.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Neogen (NEOG) Introduces New Genomic Data Management Tool
by Zacks Equity Research
Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.
Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.
Molina (MOH) Q2 Earnings Beat on High Premiums, '23 View Raised
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are aided by increased membership, and Medicaid and Medicare strength.
Neogen (NEOG) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 40% and 6.38%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?
Philips (PHG) Q2 Earnings Beat Estimates, Revenue Rise Y/Y
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.
Earnings Preview: Neogen (NEOG) Q4 Earnings Expected to Decline
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best Momentum Stocks to Buy for July 19th
by Zacks Equity Research
NEOG, OPK and PCOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 19, 2023.
New Strong Buy Stocks for July 19th
by Zacks Equity Research
SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.
Buy These 4 Stocks Following New Analyst Coverage
by Shrabana Mukherjee
The recent surge in analyst coverage for stocks such as Beazer Homes (BZH), Seadrill (SDRL), EnerSys (ENS) and Neogen (NEOG) indicates the potential for significant price appreciation in the near term.
What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?
by Zacks Equity Research
The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.
Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q2 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) second-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues, as well as the number of people served.
Will High Medical Costs Affect UnitedHealth (UNH) Q2 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) second-quarter results are likely to reflect growth in memberships and expense levels.
Why You Should Add Humana (HUM) Stock to Your Portfolio Now
by Zacks Equity Research
Humana's (HUM) strength in Individual Medicare Advantage business and state-based contract wins are likely to be major tailwinds.
Cintas (CTAS) to Post Q4 Earnings: Will Cost Woes Mar Results?
by Zacks Equity Research
Cintas' (CTAS) Q4 performance is likely to have been hurt by rising costs. However, higher volumes and prices within the Uniform Rental and Facility Services unit are likely to have aided the same.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are upbeat about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.
Earnings Estimates Moving Higher for Neogen (NEOG): Time to Buy?
by Zacks Equity Research
Neogen (NEOG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes Neogen (NEOG) a New Buy Stock
by Zacks Equity Research
Neogen (NEOG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neogen (NEOG) Awarded for its Petrifilm Plate Reader Advanced
by Zacks Equity Research
Neogen (NEOG) receives the prestigious 2023 Red Dot Award for the Petrifilm Plate Reader Advanced in Design category.
Neogen (NEOG) Introduces Improved Genomic Test for Cats
by Zacks Equity Research
Neogen's (NEOG) My CatScan 2.0 offers insightful genetic information that enables preventive cat care by tackling curable conditions.